§ 01

Overview

Gabapentin

Gabapentin

Mechanism of Action Diagram

Gabapentinoids are a class of anticonvulsant medications that have become major players in chronic pain management over the past two decades. Despite the name, they do NOT act on GABA receptors. Their mechanism is entirely through binding to the alpha-2-delta (α2δ) subunit of voltage-gated calcium channels, which reduces the release of excitatory neurotransmitters at synapses in the spinal dorsal horn.

Pregabalin (Lyrica) is FDA-approved for fibromyalgia, diabetic peripheral neuropathy, post-herpetic neuralgia, and neuropathic pain associated with spinal cord injury. Gabapentin (Neurontin) is FDA-approved for post-herpetic neuralgia and as adjunctive therapy for epilepsy. Both are used extensively off-label for various chronic pain conditions.

For myofascial pain syndrome specifically, gabapentinoids are most useful when central sensitization is present — a state of amplified pain processing in the spinal cord and brain that makes trigger points more painful, more widespread, and more resistant to peripheral treatments alone. When central sensitization develops, treating trigger points locally is necessary but often insufficient; a centrally-acting medication like a gabapentinoid can address the amplified processing that maintains the pain state.

§ 02

Mechanism of Action

Gabapentinoids produce their analgesic effects through a well-characterized molecular mechanism centered on the alpha-2-delta subunit of voltage-gated calcium channels. Understanding each step explains why these drugs are particularly effective for central sensitization but not for acute, localized pain.

Gabapentin works best for the neuropathic component of myofascial pain — the burning, tingling, and electric sensations that suggest nerve involvement.

Mechanism of Action

Mechanism of Action

Mechanism Diagram

Alpha-2-Delta (α2δ) Subunit Binding

The primary mechanism. Gabapentinoids bind with high affinity to the alpha-2-delta (α2δ) auxiliary subunit of voltage-gated calcium channels, specifically the CaV2.1 (P/Q-type) and CaV2.2 (N-type) channels. This binding reduces trafficking of the calcium channel complex to the presynaptic membrane and decreases calcium influx at presynaptic terminals in the spinal dorsal horn, particularly in laminae I and II where nociceptive afferents terminate.

Reduced Excitatory Neurotransmitter Release

By decreasing presynaptic calcium influx, gabapentinoids reduce the release of multiple excitatory neurotransmitters from primary afferent terminals: glutamate (the principal excitatory neurotransmitter in pain pathways), substance P (a key nociceptive neuropeptide), norepinephrine, and calcitonin gene-related peptide (CGRP). This dampens pain signal transmission at the first central synapse in the dorsal horn.

Anti-Allodynic & Anti-Hyperalgesic Effects

Gabapentinoids reduce both hyperalgesia (an exaggerated pain response to mildly painful stimuli) and allodynia (pain elicited by normally non-painful stimuli such as light touch or clothing contact). These phenomena are hallmarks of central sensitization and are the primary targets of gabapentinoid therapy in chronic myofascial pain.

Wind-Up Reduction

Gabapentinoids prevent wind-up — the progressive amplification of pain signals that occurs in wide-dynamic-range (WDR) neurons of the spinal dorsal horn when C-fiber nociceptors are stimulated repeatedly. Wind-up is a key mechanism of temporal summation and contributes to the escalating pain experienced with chronic trigger points.

Descending Facilitation Modulation

Emerging evidence suggests gabapentinoids may reduce descending facilitatory drive from the brainstem, specifically from rostral ventromedial medulla (RVM) ON-cells. In chronic pain states, these descending pathways shift from predominantly inhibitory to facilitatory, amplifying spinal pain processing. Gabapentinoids may help rebalance this system.

NOT GABAergic — A Critical Distinction

Despite the name "gabapentin," these drugs do NOT bind to GABA-A or GABA-B receptors, are NOT functional GABA analogues, and do NOT affect GABA synthesis, release, or reuptake at clinically relevant doses. The name reflects the original (incorrect) hypothesis during drug development. Their mechanism is entirely through alpha-2-delta calcium channel subunit binding.

Why Useful for Myofascial Pain Syndrome

When trigger points have been present for months or years, central sensitization develops — spinal cord neurons become hyperexcitable, receptive fields expand, and pain processing is amplified. Even after successful trigger point treatment (injections, dry needling, manual therapy), residual central sensitization can maintain widespread pain and tenderness. Gabapentinoids specifically target this central amplification component.
§ 03

Individual Drug Profiles

Gabapentin (Neurontin)

First-Line Generic
Half-Life5 to 7 hours (requires TID dosing for consistent plasma levels)
Onset of Effect1 to 2 weeks for initial benefit (often sleep improvement first), 4 to 8 weeks for full analgesic effect.

Pain Dosing

Start 100 to 300 mg at bedtime. Titrate by 100 to 300 mg every 3 to 7 days. Target: 900 to 3,600 mg/day in three divided doses (TID).

Bioavailability (Critical Limitation)

Non-linear and dose-dependent — a critical pharmacokinetic limitation. Bioavailability is approximately 60% at 300 mg, drops to 35% at 1,600 mg, and further to 27% at 3,600 mg. This occurs because gabapentin absorption depends on a saturable L-amino acid transporter in the proximal small intestine. At higher doses, the transporter becomes saturated and a larger fraction of the drug passes unabsorbed.

FDA Approvals

Post-herpetic neuralgia (PHN). Epilepsy (adjunctive).

Key Studies

Backonja et al. (1998) — pivotal trial for neuropathic pain. Limited Myofascial Pain Syndrome-specific randomized controlled trials. Evidence largely extrapolated from neuropathic pain and fibromyalgia literature.

Common Side Effects

Dizziness (20 to 28%), somnolence (20%), peripheral edema (8%), weight gain (average 2 to 3 kg), ataxia, cognitive slowing.

Advantages
  • No hepatic metabolism — excreted unchanged by kidneys
  • No significant drug-drug interactions (not a CYP substrate or inhibitor)
  • Inexpensive — widely available as generic ($10 to $30/month)
  • Long clinical track record with extensive safety data
  • Not a controlled substance in most states (though increasingly monitored)
Disadvantages
  • TID dosing reduces adherence (three times daily)
  • Non-linear absorption limits dose predictability at higher doses
  • Slow titration required — 4 to 8 weeks to reach therapeutic dose
  • High doses needed for some patients (up to 3,600 mg/day)
  • Somnolence and dizziness can be dose-limiting
Best For →Best for: Budget-conscious patients, patients on multiple medications where drug interactions are a concern, initial trial of gabapentinoid therapy.

Pregabalin (Lyrica)

FDA-Approved for Fibromyalgia
Half-Life6 hours (BID dosing provides consistent plasma levels)
Onset of EffectSome benefit within 1 week. Optimal analgesic effect at 4 to 6 weeks.

Pain Dosing

Start 25 to 75 mg twice daily (BID). Titrate by 75 to 150 mg/day every 3 to 7 days. Target: 150 to 300 mg BID (300 to 600 mg/day total).

Bioavailability (Major Advantage)

Linear (dose-proportional) at 90% or greater across the entire dose range — a major pharmacokinetic advantage over gabapentin. Absorption does not depend on a saturable transporter. Doubling the dose reliably doubles the plasma concentration.

FDA Approvals

Fibromyalgia. Diabetic peripheral neuropathy. Post-herpetic neuralgia. Neuropathic pain associated with spinal cord injury. Epilepsy (adjunctive).

Key Studies

Arnold et al. (2008) — 14-week RCT (J Pain) showing pregabalin 300, 450, and 600 mg/day significantly reduced pain compared with placebo in fibromyalgia. Crofford et al. (2005, Arthritis & Rheumatism) — at 450 mg/day, 29% of patients achieved at least 50% pain reduction versus 13% on placebo, with sustained effect through follow-up. Specific NNT figures vary across systematic reviews.

Common Side Effects

Dizziness (29 to 38%), somnolence (16 to 25%), weight gain (average 3 to 5 kg), peripheral edema (6 to 16%), blurred vision, dry mouth, cognitive impairment.

Advantages
  • Linear absorption — predictable, dose-proportional pharmacokinetics
  • BID dosing improves adherence versus gabapentin TID
  • Faster titration to therapeutic dose (1 to 2 weeks vs. 4 to 8 weeks)
  • FDA-approved for fibromyalgia and multiple neuropathic pain conditions
  • Stronger clinical evidence base for central pain conditions
  • Schedule V classification reflects lower (but real) abuse potential
Disadvantages
  • Expensive — brand Lyrica costs $200 to $500/month (generic pregabalin $30 to $80/month)
  • Schedule V controlled substance — DEA monitoring, potential for misuse
  • Weight gain may be more pronounced than gabapentin
  • Peripheral edema can be significant, especially in combination with thiazolidinediones
  • Euphoria reported by some patients contributes to abuse potential
Best For →Best for: Fibromyalgia-myofascial pain overlap syndromes, patients needing predictable dose-response, patients who failed gabapentin titration, patients wanting BID dosing convenience.

Gabapentin Enacarbil (Horizant)

Extended-Release Prodrug

An extended-release prodrug of gabapentin that is actively absorbed via high-capacity nutrient transporters (MCT-1 and SMVT) in the GI tract, bypassing the saturable L-amino acid transporter limitation of immediate-release gabapentin. This results in dose-proportional absorption similar to pregabalin.

Dosing600 mg once daily for restless legs syndrome, 600 mg BID for post-herpetic neuralgia.
Better bioavailability than standard gabapentin but less studied for musculoskeletal pain. Not interchangeable with gabapentin on a mg-per-mg basis.

Mirogabalin (Tarlige)

Next-Generation α2δ Ligand

A newer-generation alpha-2-delta ligand with higher binding selectivity for the α2δ-1 subunit over α2δ-2. Developed and marketed primarily in Japan by Daiichi Sankyo. Approved for peripheral neuropathic pain in Japan, South Korea, and several Asian countries.

Dosing5 to 15 mg BID (approved dosing in Japan).
Not currently available in the United States or Europe. Limited data for myofascial pain syndrome. The α2δ-1 selectivity may theoretically offer a more targeted analgesic profile with fewer cerebellar side effects (mediated by α2δ-2).
§ 04

Clinical Evidence for myofascial pain

Direct clinical trial evidence for gabapentinoids specifically in myofascial pain syndrome is limited. Most of the supporting evidence comes from neuropathic pain and fibromyalgia trials, with clinical application to myofascial pain based on the significant pathophysiological overlap — particularly central sensitization — between these conditions.

Fibromyalgia Evidence (Significant Overlap with Chronic myofascial pain)

  • Pregabalin at 450 mg/day produced at least 50% pain reduction in 29% of patients versus 13% on placebo (Crofford et al., 2005, Arthritis & Rheumatism). Mean pain scores improved across the 300, 450, and 600 mg/day arms in Arnold et al. (2008, J Pain).
  • A meaningful proportion of patients achieves clinically relevant relief, but the effect is modest at the population level — many patients see partial or no benefit.
  • Gabapentin data for fibromyalgia is more limited, with fewer large-scale RCTs

Expert Consensus and Clinical Practice

  • Expert opinion supports gabapentinoids when central sensitization is clinically evident
  • Best evidence in patients with myofascial pain plus features of central sensitization: widespread tenderness, allodynia, temporal summation, and non-restorative sleep
  • Limited evidence for acute or strictly localized myofascial pain without central sensitization features
§ 05

Central Sensitization — When to Suspect It

Central sensitization is the primary indication for adding a gabapentinoid to a myofascial pain treatment plan. Recognizing its clinical features is essential for appropriate patient selection.

Widespread pain beyond expected referred patterns

Pain extends beyond the known trigger point referred pain maps. A patient with upper trapezius trigger points should not have pain in their feet.

Allodynia

Pain from normally non-painful stimuli. Light touch, clothing pressure, or a gentle breeze causes pain. Test by lightly stroking skin with a cotton wisp.

Hyperalgesia

Exaggerated pain from mildly painful stimuli. A pinprick that should rate 2/10 is reported as 7/10. Pain is disproportionate to the stimulus.

Temporal summation (wind-up)

Repeated identical stimuli produce progressively increasing pain. Tap the same spot 10 times with the same force — if each tap hurts more than the last, temporal summation is present.

Expanding receptive fields

The area of pain has gradually spread over weeks to months, involving more body regions than the original complaint. New areas become tender without new injury.

Sleep disruption, cognitive fog, fatigue

Central sensitization is associated with non-restorative sleep, difficulty concentrating ("fibro fog"), and persistent fatigue — features shared with fibromyalgia.

Central Sensitization Inventory (CSI) score of 40 or above

The CSI is a validated 25-item self-report questionnaire. Scores of 40 or above (out of 100) indicate clinically relevant central sensitization and predict better response to centrally-acting medications.
§ 06

Side Effects & Safety

§ 07

Gabapentin vs Pregabalin — Head to Head

Gabapentin vs Pregabalin

Gabapentin vs Pregabalin

Head to Head
Feature
GabapentinPregabalin

Absorption

Non-linear, saturable (60% at 300 mg, 27% at 3,600 mg)
Linear, dose-proportional (≥90% at all doses)

Dosing Frequency

Three times daily (TID)
Twice daily (BID)

Time to Therapeutic Dose

4 to 8 weeks
1 to 2 weeks

Typical Target Dose

900 to 3,600 mg/day
300 to 600 mg/day

FDA for Fibromyalgia

No
Yes

Monthly Cost (Generic)

$10 to $30
$30 to $80

Monthly Cost (Brand)

N/A (generic only)
$200 to $500 (Lyrica)

DEA Schedule

Not scheduled (federally); some states schedule
Schedule V (all states)

Drug Interactions

Minimal — no CYP metabolism
Minimal — no CYP metabolism

Weight Gain (Average)

2 to 3 kg
3 to 5 kg

Abuse Potential

Low but increasing reports
Moderate (euphoria more common)

Renal Dosing

Required — dose reduce in CKD
Required — dose reduce in CKD
§ 08

Gabapentinoids vs TCAs vs SNRIs

Three major centrally-acting drug classes are used for chronic myofascial pain with central sensitization. The choice depends on the patient's specific symptom profile, comorbidities, and tolerability.

Feature
GabapentinoidsTCAsSNRIs

Primary Mechanism

α2δ calcium channel subunit binding → reduced excitatory neurotransmitter release
Serotonin and norepinephrine reuptake inhibition + sodium channel blockade + NMDA antagonism
Serotonin and norepinephrine reuptake inhibition (selective)

Best When

Central sensitization present, neuropathic features, sleep disrupted
Widespread pain, poor sleep, tension headache overlap, depression
Depression comorbidity, fatigue, fibromyalgia overlap, moderate pain

Prototype Drug

Pregabalin 300 to 450 mg/day or Gabapentin 1,800 to 3,600 mg/day
Amitriptyline 10 to 75 mg at bedtime or Nortriptyline 25 to 75 mg at bedtime
Duloxetine 60 to 120 mg/day or Milnacipran 50 mg BID

Sleep Benefit

Moderate — improves sleep architecture, reduces arousals
Strong — sedating, increases slow-wave sleep
Minimal to moderate — some may cause insomnia

Weight Effect

Gain (2 to 5 kg average)
Gain (often more than gabapentinoids)
Neutral to mild loss (duloxetine) or gain (milnacipran neutral)

Cardiac Safety

No cardiac concerns
QT prolongation risk, contraindicated in cardiac conduction disease
Mild blood pressure elevation possible

Drug Interactions

Minimal
Numerous — CYP2D6 substrate, many interactions
Moderate — serotonin syndrome risk, CYP interactions
§ 09

Practical Prescribing for myofascial pain

When to Consider Gabapentinoids for myofascial pain

  • Central sensitization features are present (allodynia, widespread tenderness, temporal summation)
  • Sleep is significantly disrupted by pain (gabapentinoids improve sleep architecture)
  • TCAs are not tolerated (cardiac issues, anticholinergic side effects, excessive sedation)
  • SNRIs are insufficient or contraindicated
  • Neuropathic pain features coexist with myofascial trigger points
  • Patient has fibromyalgia-myofascial pain overlap syndrome

Choosing Between Gabapentin and Pregabalin

  • Start with gabapentin if: cost is a concern, patient prefers non-scheduled medication, initial trial
  • Start with pregabalin if: fibromyalgia is comorbid, need predictable dosing, gabapentin failed or was poorly tolerated, patient adherence is a concern (BID vs TID)
  • Switch from gabapentin to pregabalin if: inadequate response at 1,800+ mg/day, non-linear absorption is suspected of limiting efficacy, TID dosing is problematic

Titration Principles

  • Start LOW: gabapentin 100 to 300 mg at bedtime, pregabalin 25 to 75 mg at bedtime
  • Titrate SLOW: increase every 3 to 7 days as tolerated
  • Target sleep first: initial bedtime dosing often improves sleep before pain
  • In elderly patients: start at half the usual starting dose and titrate even more slowly
  • Allow 4 to 8 weeks at therapeutic dose before judging efficacy

Combination Strategies

  • Gabapentinoids + physical therapy: gabapentinoids reduce central sensitization, facilitating participation in manual therapy and exercise programs
  • Gabapentinoids + trigger point injections: address both central (gabapentinoid) and peripheral (injection) pain generators
  • Gabapentinoids + SNRI: combination may provide additive benefit via different mechanisms (use caution, more side effects)
  • Avoid gabapentinoid + opioid combinations when possible (respiratory depression risk)
  • Do NOT combine gabapentin and pregabalin — same mechanism, no additive benefit, more side effects

Duration and Reassessment

  • Plan for a 3 to 6 month trial at therapeutic dose
  • Reassess at regular intervals — is central sensitization improving?
  • If trigger points resolve with treatment, begin slow taper of gabapentinoid
  • Some patients require long-term maintenance (especially chronic widespread pain or fibromyalgia overlap)
  • Taper by 25 to 33% per week when discontinuing — never stop abruptly
Key Takeaways

  1. Gabapentinoids (gabapentin and pregabalin) act by binding the alpha-2-delta subunit of voltage-gated calcium channels — they are NOT GABAergic despite the name.

  2. Their primary role in myofascial pain is treating central sensitization — the amplified spinal cord pain processing that develops with chronic trigger points.

  3. Pregabalin has linear absorption and BID dosing, making it pharmacokinetically superior to gabapentin, but it is more expensive and is a Schedule V controlled substance.

  4. Gabapentin has non-linear, saturable absorption that limits bioavailability at higher doses, but it is inexpensive, widely available, and has minimal drug interactions.

  5. Direct evidence for gabapentinoids specifically in myofascial pain is limited — most evidence is extrapolated from fibromyalgia and neuropathic pain trials.

  6. Best candidates are patients with myofascial pain plus features of central sensitization: widespread tenderness, allodynia, temporal summation, sleep disruption, and CSI scores of 40 or above.

  7. Start low and titrate slow — allow 4 to 8 weeks at therapeutic dose before assessing efficacy.

  8. Combine with physical therapy and trigger point treatments for a multimodal approach addressing both peripheral and central pain mechanisms.

  9. FDA warning: respiratory depression risk when combined with opioids or other CNS depressants. Never stop abruptly — taper over at least 1 week to avoid seizures.

  10. Plan a finite trial (3 to 6 months), then reassess. Taper if trigger points have resolved and central sensitization has improved.